Teladoc Company Profile (NYSE:TDOC)

Teladoc trades on the New York Stock Exchange (NYSE) under the ticker symbol "TDOC."

Teladoc, Inc. (NYSE:TDOC) released its earnings results on Wednesday, August, 2nd. The company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by $0.02. The business earned $44.60 million during the quarter, compared to the consensus estimate of $44.39 million. Teladoc had a negative return on equity of 19.88% and a negative net margin of 47.75%. The firm's revenue for the quarter was up 68.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.38) earnings per share. View Teladoc's Earnings History.

Teladoc is scheduled to release their next quarterly earnings announcement on Wednesday, October, 25th 2017. View Earnings Estimates for Teladoc.

Teladoc issued an update on its FY17 earnings guidance on Wednesday, August, 2nd. The company provided earnings per share (EPS) guidance of ($1.55)-($1.52) for the period, compared to the Thomson Reuters consensus estimate of ($0.99). The company issued revenue guidance of $230-$235 million, compared to the consensus revenue estimate of $232.27 million.Teladoc also updated its Q3 guidance to ($0.58)-($0.56) EPS.

11 analysts have issued 1-year target prices for Teladoc's shares. Their forecasts range from $31.00 to $42.00. On average, they anticipate Teladoc's share price to reach $38.00 in the next twelve months. View Analyst Ratings for Teladoc.

Here are some recent quotes from research analysts about Teladoc stock:

• 1. According to Zacks Investment Research, "The stock of Teladoc has outperformed the industry year to date. The company is witnessing steady business growth with insurers and customers increasingly embracing telehealth. It’s organic growth initiative remains on track. With a number of acquisitions completed since its inception, the company has expanded its distribution capabilities and broadened its service offering. Also the company boasts an impressive clientele. The company has also provided strong guidance for 2017. The company has incurred significant losses in each period since its inception in 2002. Teladoc has been unable to generate cash from operations and we have doubts over its ability to do so in the coming quarters. Its high debt level has caused a spike in interest expense which has dented its operating margins." (10/18/2017)
• 2. Cantor Fitzgerald analysts commented, "Management indicates a high confidence level that the newly-expanded relationship (shared savings with no PMPM) with Aetna will help to grow revenue and earnings over time." (9/26/2017)
• 3. Cowen and Company analysts commented, "We are positive on TDOC's partnership with Accolade as it should help drive utilization for members entitled to both benefits. For clients with the combined offering, it has demonstrated improvements in utilization, with mgmt noting ~30% higher utilization. The partnership is already embedded into 2017 guidance, which gives us incremental comfort in the implied utilization ramp." (3/16/2017)
• 4. Chardan Capital analysts commented, "After market close on Wed., TDOC reported earnings with a beat and a mixed guide for 2017. For 4Q16, Teladoc beat the Street consensus by 2% on the topline and by $0.04 on the bottom line. Management guided to topline growth in 2017 of 48%, in-line with Street consensus and re-affirmed its target of being adj. EBITDA breakeven in 4Q17. Management also guided to more EBITDA loss in 2017 than the Street expected in the first 3 quarters driven by various investments in growth. We adjust our estimates down slightly and in-line with Management Guidance for 2017. We raise our PT to $28 based on multiple expansion we see in 2017 as TDOC's operating characteristics improve relative to valuation comps and investor confidence grows in the company's execution." (3/2/2017)

Some companies that are related to Teladoc include Nektar Therapeutics (NKTR), Hikma Pharmaceuticals Plc (HKMPF), Acadia Healthcare Company (ACHC), Patterson Companies (PDCO), LivaNova PLC (LIVN), Insulet Corporation (PODD), Agios Pharmaceuticals (AGIO), Molina Healthcare (MOH), Sarepta Therapeutics (SRPT), AveXis (AVXS), Chemed Corp. (CHE), Mallinckrodt PLC (MNK), Spark Therapeutics (ONCE), Penumbra (PEN), Advanced Accelerator Applications S.A. (AAAP), HealthEquity (HQY), Ligand Pharmaceuticals Incorporated (LGND) and Neogen Corporation (NEOG).

Teladoc's management team includes the folowing people:

• David B. Snow Jr., Independent Chairman of the Board
• Jason Gorevic, President, Chief Executive Officer, Director
• Mark J. Hirschhorn, Chief Financial Officer, Chief Operating Officer, Executive Vice President
• Peter N. Nieves, Executive Vice President, Chief Revenue Officer
• Gabriel R. Cappucci, Senior Vice President, Chief Accounting Officer, Controller
• Michael H. King, Chief Sales Officer
• Adam C. Vandervoort, Chief Legal Officer and Secretary
• Helen Darling, Independent Director
• William H. Frist M.D., Independent Director
• Michael S. Goldstein CPA, Independent Director

(TDOC) raised $112 million in an initial public offering on Wednesday, July 1st 2015. The company issued 7,000,000 shares at $15.00-$17.00 per share. J.P. Morgan and Deutsche Bank Securities acted as the underwriters for the IPO and William Blair, Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.

Shares of Teladoc can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Teladoc stock can currently be purchased for approximately $34.00.